rp2,nivolumab,rp-1,vusolimogene
replimune,bms
['rp2 ', 'ignyte', 'melanoma', 'rp1', 'replimune', '$repl']
replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting - health stocks hub $repl 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2